?Product Name?: tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate (Edoxaban Intermediate 2)
?CAS No.?: 1210348-34-7

?? ?Product Overview?
A high-purity pharmaceutical intermediate for synthesizing ?Edoxaban? (CAS 480449-70-5), a ?direct oral anticoagulant (DOAC)? used to prevent stroke and systemic embolism. With ?≥99% purity? (HPLC-certified), it ensures consistency in API manufacturing and compliance with pharmacopeial standards. Suitable for industrial-scale production and R&D of anticoagulant drugs. Available in quantities from ?1g to 25kg? with customizable packaging.

?? ?Key Advantages?
? ?Ultra-High Purity?: ≥99% (HPLC/GC-tested), minimizing impurities in API batches.
?? ?Flexible Supply?: Bulk packaging (25kg/drum) and lab-scale options (1g–5g) for diverse needs.
?? ?Critical Role?: Key intermediate in Edoxaban synthesis, supporting a $2.8B+ anticoagulant market.

?? ?Applications?

1. ?API Production?: Essential for large-scale Edoxaban synthesis.

2. ?Quality Control?: Used in impurity profiling and batch validation for regulatory compliance.

3. ?Generic Drug R&D?: Accelerates post-patent development of cost-effective anticoagulants.

?? ?Quality Certification?

• ?Testing Methods?: HPLC, GC, NMR, and mass spectrometry.

• ?Compliance?: Meets ISO 9001 and ICH guidelines for pharmaceutical intermediates.

?? ?Market Trends?
The demand for Edoxaban intermediates is rising due to ?patent expirations (2024–2026)? and the expansion of generic DOAC markets. The Asia-Pacific region dominates API production, with suppliers offering ?GMP-compliant intermediates? gaining a competitive edge. The global anticoagulant market is projected to grow at ?7.9% CAGR (2025–2030)?.